Metypred Forte (Methylprednisolone Sodium Succinate)

Metypred Forte, a glucocorticoid administered intravenously or intramuscularly, is used in acute inflammatory and immune‑mediated conditions.

• Multiple sclerosis relapse: reduces inflammation and accelerates neurological recovery.
• Severe allergic reactions or anaphylaxis: rapidly suppresses hypersensitivity and airway edema.
• Acute asthma exacerbation: improves bronchial airflow by decreasing airway inflammation.
• Rheumatic disease flare: alleviates joint swelling and pain in rheumatoid arthritis.
• Dermatologic emergencies: controls severe skin inflammation such as Stevens‑Johnson syndrome.

• Methylprednisolone sodium succinate acts as an agonist at intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and binds glucocorticoid response elements. This modulates gene transcription, leading to decreased production of pro‑inflammatory cytokines, inhibition of leukocyte migration, and suppression of immune cell activation, thereby producing anti‑inflammatory and immunosuppressive effects.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Hyperglycemia: elevated blood glucose levels, especially in diabetic patients.
• Fluid retention: peripheral edema and weight gain.
• Hypertension: increased blood pressure.
• Mood changes: irritability, anxiety, or insomnia.
• Gastrointestinal discomfort: nausea or abdominal pain.
• Increased appetite: leading to weight gain.

Serious or Rare Side Effects

• Adrenal suppression: risk of adrenal insufficiency on abrupt discontinuation.
• Severe infection: heightened susceptibility to bacterial, viral, or fungal infections.
• Gastrointestinal bleeding: ulceration or hemorrhage.
• Avascular necrosis: bone tissue death, particularly in hips.
• Psychosis or severe mood disorders: hallucinations or depression.
• Anaphylaxis: rare but life‑threatening allergic reaction.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for complications.

• Infection screening: assess for active infections before use.
• Blood glucose monitoring: especially in diabetic or pre‑diabetic patients.
• Psychiatric assessment: watch for mood swings or psychotic symptoms.
• Cardiovascular caution: use carefully in patients with hypertension or heart disease.
• Tapering requirement: avoid abrupt cessation to prevent adrenal crisis.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Methylprednisolone may alter the activity of several concomitant medicines.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase steroid levels.
• Live vaccines: risk of uncontrolled infection.
• NSAIDs or anticoagulants: heightened risk of gastrointestinal bleeding.
• Diuretics (especially loop): may exacerbate electrolyte imbalances.
• Antifungal azoles: can potentiate glucocorticoid effects.

Moderate Interactions (Monitor Closely)

• Antidiabetic agents: may require dose adjustment due to hyperglycemia.
• Antihypertensives: possible reduction in blood pressure control.
• Anticholinergic drugs: additive central nervous system effects.
• Osteoporosis treatments: monitor bone density.
• CYP3A4 inducers (e.g., rifampin): may reduce steroid efficacy.